Commentary · 8 Jun 2026
Conference abstractPublished 22 Jan 2019
Mild cognitive impairment
Tehran University of Medical Sciences, Iran
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Mild Cognitive Impairment (MCI) is intended: An intermediate stage between normal aging and the development of pathologic aging and dementia. An intermediate stage between the expected cognitive decline of normal aging and the more-serious decline of dementia. It can involve problems with memory, language, thinking and judgment. There should be evidence of lower performance that is greater than would be expected for the patient’s age and educational background. If repeated assessments are available, then a decline in performance should be evident over time. Scores on cognitive tests for individuals with MCI are typically 1 to 1.5 SD below the mean for their age and education matched peers on culturally appropriate normative data. In illiterate people many of neuropsychological assessment could not detect real MCI and any clinician should consider the level of education and social activity in diagnosis MCI and Dementia. It is emphasized that these ranges are guidelines and not cutoff scores. The term MCI has been in the literature for almost 4 decades. MCI was originally conceptualized by a research group from New York University in 1994 using the six stages from the global deterioration scale (GDS; Reisberg et al.,1982). In 2011, the National Institute on Aging (NIA) and the Alzheimer’s Association convened workgroups to develop criteria for the entire AD spectrum. Taken together, these criteria offer an exciting advancement in the diagnosis of MCI; however, the inclusion of biomarkers and imaging is only considered appropriate as part of clinical research protocols and not as part of standard clinical practice. The DSM-5 introduced the term Neuro Cognitive Disorder (NCD). The terms dementia and MCI were avoided because their use is closely associated with geriatric disorders, while NCD encompasses acquired cognitive impairment of all causes at all ages. They noted that mild NCD encompasses a more diverse group of entities including mild acquired impairments in younger individuals. Impairments that may be transient, static, or even reversible. While no pharmacologic therapies are currently approved by the US FDA for MCI due to AD, lifestyle modifications and cognitive and behavioral therapies can be useful.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Alzheimers Disease & Parkinsonism.
Perspective · 8 Jun 2026
Oxidative Stress and Its Role in Neuronal Degeneration: Mechanisms and Implications
Commentary · 8 Jun 2026
Understanding the Pathophysiology of Prion-Induced Dementia
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Zahra Vahabi”
